Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005023 · ClinicalTrials.gov registry record · Phase 1

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by University of Washington.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00005023 is a Phase 1 study of Breast Cancer and Lung Cancer that has completed, run by University of Washington. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005023, a Phase 1 study of Breast Cancer and Lung Cancer, has completed, sponsored by University of Washington.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in treating patients who have stage III or stage IV cancer.

Conditions Studied

Breast Cancer Lung Cancer Ovarian Cancer

Interventions

  • BIOLOGICAL sargramostim
  • BIOLOGICAL HER-2/neu peptide vaccine

Study Locations (1)

Washington

  • University of Washington School of Medicine - Seattle

Trial Details

FieldValue
Start Date 1999-03
Est. Completion 2001-01
Phase Phase 1

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00005023

The ClinicalTrials.gov registry entry for NCT00005023 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which sargramostim is the first listed.

NCT00005023 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00005023 about?

NCT00005023 is a clinical study titled "Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer". RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in trea...

What is the current status of trial NCT00005023?

This trial is currently completed. It is a Phase 1 study. The study started on 1999-03. Estimated completion is 2001-01.

What conditions does trial NCT00005023 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Ovarian Cancer.

What interventions are being tested in trial NCT00005023?

The interventions under investigation include: sargramostim (BIOLOGICAL), HER-2/neu peptide vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00005023?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005023 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Lung Cancer

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.